Novo Nordisk's CEO Has a Comeback Plan
Summary
Novo Nordisk CEO Mike Douma discusses the company’s strategy to regain market share from rival Eli Lilly in the weight loss drug sector. He addresses recent setbacks, including the underperformance of the drug CagriSema, while highlighting the success of the Wegovy pill and plans to lower US prices. Douma emphasizes shifting focus from pure weight loss magnitude to broader health outcomes and expanding access through digital channels.
Topics discussed
Novo Nordisk's market share loss to Eli Lilly
Show intro and sponsor advertisements
Shifting from patient-centric to consumer mindset
Zepbound efficacy vs. long-term health benefits
CagriSema trial results and stock valuation impact
Wegovy pill success and sponsor ads
Wegovy pill launch and peptide technology
Price cuts for Wegovy and Ozempic in the US
Future pipeline: UBT-251 and next-gen drugs
CEO's outlook on purpose and long-term strategy
Listen ad-free on Castria